Leerink on BioMarin Pharma (BMRN): 'We continue to hold a more cautious view on the outlook for Voxzogo'
Tweet Send to a Friend
Leerink Partners analyst Joseph Schwartz reiterated a Market Perform rating and $62.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
